ir.biostemtechnologies.com Open in urlscan Pro
2606:4700:10::ac43:688  Public Scan

Form analysis
1 forms found in the DOM

POST

<form id="accessibility-dictionary-form" enctype="multipart/form-data" mode="#" method="POST" tabindex="-1" autocomplete="on">
  <input type="text" tabindex="0" class="no-translate" id="accessibility-dictionary-search" accessible-i18n="dictionaryPlaceholder" name="accessibility-dictionary-search" autocomplete="on" placeholder="Start typing to search the online dictionary"
    aria-label="Search the online dictionary...">
</form>

Text Content

Skip to Main Content

Open Accessibility Options
Open the Accessible Link Tree

 * Contact IR
 * FAQS
 * Corporate Website

Investor relations
 * Overview
 * News
 * Events
 * Financials
   * SEC Filings
   * Quarterly Results
   * Annual Reports
 * Stock Info
 * Resources
   * Board of Directors
   * Management Team
   * Scientific Advisory Board
   * Analysts
   * Investor Email Alerts
 * Corporate Website

Select Page
 * Overview
 * News
 * Events
 * Financials
   * SEC Filings
   * Quarterly Results
   * Annual Reports
 * Stock Info
 * Resources
   * Board of Directors
   * Management Team
   * Scientific Advisory Board
   * Analysts
   * Investor Email Alerts
 * Corporate Website
 * Contact IR
 * FAQS
 * Corporate Website


INVESTOR RELATIONS



INVESTORS


VIEW THE LATEST STOCK TRADING INFORMATION

Review BioStem’s latest trading data, historical quotes, volume, and key
statistics.

Learn More

NEWS


SIGN UP WITH EMAIL ALERTS TODAY.

Get news, filings, and events directly in your inbox with our automated Email
Alerts

Sign Up


BIOSTEM TECHNOLOGIES INC (BSEM)

$9.88650.46(4.84%)

September 12, 2024 1:55 PMETSeptember 12, 2024 Volume: 8,196
USDOTC Pink CurrentDelayed PriceMarket Closed


DETAILED QUOTE

Show DataShow Chart

DateOpenHighLowClose2024-09-129.509.979.509.88652024-09-119.959.959.409.432024-09-109.6010.209.459.632024-09-099.579.949.409.582024-09-0610.0210.029.509.572024-09-0510.6010.6010.0510.102024-09-0410.9811.0010.5010.602024-09-0311.0011.0010.6011.002024-08-3011.27211.27211.0011.022024-08-2911.4611.5911.09411.302024-08-2811.5011.5911.4311.4592024-08-2711.6811.6911.4311.602024-08-2611.6212.2011.5211.632024-08-2311.3612.1011.3511.492024-08-2211.5411.7711.0111.302024-08-2110.5211.6510.5211.002024-08-2011.2011.2910.3010.502024-08-1911.5711.7011.0211.242024-08-1611.5212.4911.5211.552024-08-1512.5113.1011.1111.992024-08-1413.6513.8012.2012.622024-08-1313.3714.3212.7513.552024-08-1211.5113.0511.0712.50

More
   
 * 1d
 * 5d
 * 1m
   
 * 3m
   
 * 6m
   
 * 1y
   
 * 5y
   


DAILY AND TOTAL COMPANY STATISTICS

Last
9.8865
$  Chg
0.4565
Open
9.50
High
9.97
Beta
1.882
Year High
52 week high modal15.50
Market Cap
161.02m
PB Ratio
-26.72
Average Volume (30 Day)
39.15k
Volume
8,196
% Chg
4.84%
Prev. Close
9.43
Low
9.50
VWAP
9.71673
Year Low
52 week high modal1.49
Total Shares
16.29m
Shares Out
16.29m
Float
16.29m
Exchange
OTCPK



SYMBOL

OTC : BSEM

PRICE

$9.89
September 12, 2024 1:55 PMETSeptember 12, 2024

VOLUME

8,196

CHANGE

0.46(4.84%)
Delayed up to 15 minutes


INVESTOR RELATIONS


BIOSTEM TECHNOLOGIES

BioStem Technologies is a leading innovator focused on harnessing the natural
properties of perinatal tissue in the development, manufacture and
commercialization of allografts for regenerative therapies. The Company is
focused on manufacturing products that change lives, leveraging its proprietary
BioRetain® processing method. BioRetain® has been developed by applying the
latest research in regenerative medicine, focused on maintaining growth factors
and preserving tissue structure. BioStem Technologies’ quality management system
and standard operating procedures have been reviewed and accredited by the
American Association of Tissue Banks (AATB). These systems and procedures are
established per current Good Tissue Practices (cGTP) and current Good
Manufacturing Processes (cGMP). Its portfolio of quality brands includes
AmnioWrap2®, VENDAJE®, VENDAJE AC® and VENDAJE OPTIC®. Each BioStem Technologies
placental allograft is processed at the Company’s FDA registered and AATB
accredited site in Pompano Beach, Florida.

PRESS RELEASES


LATEST NEWS


BIOSTEM TECHNOLOGIES, INC. TO PRESENT AT THE H.C. WAINWRIGHT 26TH ANNUAL GLOBAL
INVESTMENT CONFERENCE IN NEW YORK ON SEPTEMBER 9TH AT 3:30 PM ET

Aug 29, 2024

BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global
Investment Conference in New York on September 9th at 3:30 PM ET Advanced wound
care MedTech company recently reported a record second-quarter with $116.4M in
revenue for H1, 2024 POMPANO...


BIOSTEM RECEIVES INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL TO ADVANCE CLINICAL
STUDY EVALUATING THE VALUE OF VENDAJE® COMPARED TO THE STANDARD OF CARE FOR
NON-HEALING DIABETIC FOOT ULCERS

Aug 21, 2024

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical
Study Evaluating the Value of Vendaje® Compared to the Standard of Care for
Non-Healing Diabetic Foot UlcersStudy supports BioStem’s strategic growth
initiatives and accelerates...


BIOSTEM TECHNOLOGIES REPORTS RECORD SECOND QUARTER 2024 REVENUE OF $74.5 MILLION

Aug 12, 2024

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
Company reports transformative second-quarter revenue, contributing to a record
total of $116.4 million in revenue for the first half of 2024 AmnioWrap2
continues to be a major growth...

All News


QUARTERLY
RESULTS


STOCK
INFORMATION


PRESENTATIONS
& BROCHURES


UPCOMING
EVENTS


 * Home
 * Our Science
 * Products
 * Resources
 * About Us
 * Contact Us

 * FAQS
 * CAREERS
 * TERMS AND CONDITIONS
 * PRIVACY POLICY
 * SHIPPING POLICY
 * REFUND POLICY
 * COOKIE POLICY

 * RSS
 * Instagram
 * X

© 2024 BioStem Technologies, Inc. All Rights Reserved. Use of this site is
subject to certain Terms Of Use and Privacy Policy.

For screen reader problems with this website, please call (954) 380-8342 for
assistance.

Disclaimer

You are about to review presentations, reports and/or filings of BioStem
Technologies, Inc., that contain time-sensitive information. The information
contained therein is only accurate as of the date thereof. BioStem Technologies,
Inc. will not be reviewing or updating the material that is contained in these
items after the date thereof. The information contained therein may be updated,
amended, supplemented or otherwise altered by subsequent presentations, reports
and/or filings by BioStem Technologies, Inc.

I Accept I Decline

×
biostemtechnologies.com


We believe your data is your property and support your right to privacy and
transparency.
Select a Data Access Level and Duration to choose how we use and share your
data.
NecessaryAccept All
1 month6 months12 months

Highest level of privacy. Data accessed for necessary basic operations only.
Data shared with 3rd parties to ensure the site is secure and works on your
device

Balanced experience. Data accessed for content personalisation and site
optimisation. Data shared with 3rd parties may be used to track you and store
your preferences for this site.

Highest level of personalisation. Data accessed to make ads and media more
relevant. Data shared with 3rd parties may be use to track you on this site and
other sites you visit.

Consent Preferences
Use the toggles below to specify your data sharing purposes for this website.
Basic Operations
This type of sharing is necessary for us to access the data we need to make sure
the website is secure and working properly.
Data Accessed:
 * Anonymous data like browser name and version
 * Pseudonymous data like authentication token

Content Personalization
When enabled, you allow us to save your preferences and create a profile about
you so we can deliver personalized content.
Data Accessed:
 * Anonymous data like device type, model and operating system
 * Pseudonymous data like site browsing preferences
 * Personal data like your IP address and location

Site Optimization
When enabled, you allow us to monitor your behavior so we can analyze and
improve the services on our website for all visitors.
Data Accessed:
 * Anonymous data like the address of the previously visited website (HTTP
   Referer)
 * Pseudonymous data like website activity identifiers
 * Personal data like content, search and purchase history

Ad Personalization
When enabled, you allow us access to share data with our advertising partners
that build profiles about you across multiple websites.
Data Accessed:
 * Anonymous data like affiliate referral links
 * Pseudonymous data like identifiers used to track and profile users
 * Personal data like your age, gender and demographics

Protection & Metrics
View your consent record, and the list of 3rd parties blocked and allowed based
on your settings.
Consent Metrics

Consent ID—Date of Consent—Data Access Level—Purpose Categories—Duration of
Consent—

Privacy Protection
Services Blocked
 * —

Services Allowed
 * —

Save my preferences
 * Customize

ArabicChineseDanishDutchEnglishEspañolFinnishFrenchGermanHebrewHungarianHindiItalianJapaneseKoreanMalayNorwegianSwedishSerbian
LatinSerbian CirillicPolishPortugueseTamil


All Accessible


CHOOSE A SAFE BROWSING PROFILE

Active
ONOFF
Color Blindness Adjustments
Color adjustment for colorblind users.
Selecting a color profile below will make the screen colors more distinct for
each profile type.

RED-GREEN COLOR BLINDNESS

Deuteranomaly
Protanomaly
Protanopia
Deuteranopia

RED-GREEN COLOR BLINDNESS

Tritanopia
Tritanomaly

OTHER COLOR BLINDNESS

Achromatopsia
Achromatomaly
ONOFF
Seizure Safe Mode
Reduces saturation and stops animations.
This mode reduces the risk of seizure that result from flashing or blinking
animations and risky color combinations by reducing saturation and stopping
animations, transitions, and videos.
ONOFF
Visually Impaired Mode
Makes the visual elements more distinct.
This mode adjusts visual elements on the screen to assist users with visual
impairment.
ONOFF
Cognitive Disability Mode
Improves identification of elements.
This mode provides assistive highlighting of titles and links to allow users
with cognitive disabilities to identify and navigate page elements.
ONOFF
ADHD/Focus Friendly Mode
Reduces distrmodes and improves focus
This mode reduces distrmodes to help users with ADHD and Neurodevelopmental
disorders to easier reading, browsing, and focusing on content.
ONOFF
Assistive Navigation Mode
Enables keyboard navigation with screen reader
This mode allows keyboard navigation throughout the page, and includes a screen
reader for assistive navigation.

CONTENT CONTROL

Readable Font
Dyslexia Font
Highlight Titles
Highlight Links
Text Magnifier
Content Scaling
Reset
Font Size
Reset
Line Height
Reset
Letter Spacing
Reset
Left Aligned
Center Aligned
Right Aligned

DESIGN CONTROL

Dark Contrast
Invert Colors
light Contrast
Monochrome
High Contrast
High Saturation
Low Saturation
Adjust Text Colors
Remove
Adjust Title Colors
Remove
Adjust Background Colors
Remove

ORIENTATION CONTROL

Mute Sounds
Hide Images
Reading Guide
Stop Animations
Reading Mask
Highlight Hover
Highlight Focus
Large Cursor
Screen Reader
Keyboard Navigation
Accessibility Statement
Page Link Tree


ACCESSIBILITY STATEMENT

We are committed to ensuring digital accessibility for people with disabilities.
We are continually improving the user experience for everyone and applying the
relevant accessibility standards and best practices regularly.


CONFORMANCE STATUS

The Web Content Accessibility Guidelines (WCAG) define requirements for
designers and developers to improve accessibility for people with disabilities.
It defines three levels of conformance: Level A, Level AA, and Level AAA. 

We have installed an automatic accessibility tool that runs in the background.
This tool runs Ai and machine learning to remediate accessibility deficiencies
in the HTML code. In addition, it provides an interface that allows visitors to
manipulate their browsing experience. The complete toolset aims to assist this
site in conforming as closely as possible to the standards by the WCAG 2.1 Level
AA.


ADDITIONAL ACCESSIBILITY CONSIDERATIONS

Although our goal is WCAG 2.1 Level AA conformance, we have also applied some
Level AAA Success Criteria: Images of text are only used for decorative
purposes. Some WCAG 2.1 Level AA requirements are not included in the
remediation process as they are outside of the scope of the website source code,
including but not limited to video captions. 

Measures taken by this website to achieve compliance

 * Complete WCAG 2.1 Level AA website audit and remediation on page load. All
   on-page elements are scanned and reviewed against our accessibility standards
   library to ensure compliance. If remediation is required, the element is
   tagged, and our Ai remediation tool makes necessary, non-invasive corrections
   on the client-side of the site

 * Auto Image and Link recognition and remediation for content that does not
   contain alt or title text for users that require screen reader access;
   descriptions are stored for user adjustment to assist our machine learning
   algorithms

 * Quick access to search Meriam Website for definitions and pronunciations of
   words.

 * Colorblindness adjustments to improve distinction between colors for
   Red-green color blindness (Deuteranomaly, Protanomaly, Protanopia,
   Deuteranopia), Blue-yellow color blindness (Tritanopia, Tritanomaly), Other
   color blindness (Achromatopsia, Achromatomaly)

 * Reset fonts to Arial or Implementation of Dyslexia friendly font 

 * Ability to Highlight Titles and Links

 * Text Magnification

 * Content, Font, Line Height, Line Spacing Scaling, and Zoom

 * Content alignment including left, center, and right

 * Dark and Light Contrast modes and High Contrast that increases contrast ratio
   to 135%, and complete inversion of colors

 * Saturation adjustments including High (140% saturation), Low (90%
   saturation), Monochrome (0% saturation)

 * Complete element color control including Title, Font, and background color
   adjustments with color-safe color palettes to ensure optimal contrast ratio
   of 4.5%

 * Ability to stop motion (videos, animated graphics, web element transitions,
   etc.), hide all images, and mute sounds

 * Simple reading guide or more elaborate page mask to assist users in focusing
   on-page content

 * Highlight element on hover or focus to ensure both keyboard and mouse users
   can orient themselves on the focused element

 * A screen reader that reads back page content on highlight 

 * Complete keyboard navigation control

 * Aggregated settings into browsing profiles to quickly deploy accessibility
   configurations for multiple user types.


COMPATIBILITY WITH BROWSERS AND ASSISTIVE TECHNOLOGY

We strive to be compatible with the following assistive technologies:

 * Google Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS,
   and NVDA (screen readers), both for Windows and for MAC users.


TECHNICAL SPECIFICATIONS

Accessibility of this site relies on the following technologies to work with the
particular combination of web browsers and any assistive technologies or plugins
installed on your computer:

 * HTML

 * WAI-ARIA

 * CSS

 * JavaScript

These technologies are relied upon for conformance with the accessibility
standards used.


NOTES

While our main goal is to make the entire site accessible to all users, there is
a possibility that some pages may not have been discovered or do not have a
satisfactory accessibility remediation solution at this time. We are committed
to constantly improving the accessibility of this site to ensure it is
accessible to all.


MOVE OR HIDE THE ACCESSIBILITY PANEL




Hide WidgetHide for 1 DayHide for 1 WeekHide for 1 MonthHide for 1 YearSelect a
length of time to hide the accessibility widget. If you wish to show the widget
before this period ends, you will need to clear your site cookies.Confirm and
Hide


PAGE LINK TREE

PAGE LANDMARKS

 * Banner
 * Navigation
 * Navigation
 * Main
 * Contentinfo

PAGE LINKS

 * CONTACT IR
 * FAQS
 * Corporate Website
 * OVERVIEW
 * NEWS
 * EVENTS
 * FINANCIALS
 * STOCK INFO
 * SEC Filings
 * Quarterly Results
 * Annual Reports
 * Board of Directors
 * Management Team
 * Scientific Advisory Board
 * Analysts
 * Investor Email Alerts
 * BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual
   Global Investment Conference in New York on September 9th at 3:30 PM ET
 * BioStem Receives Institutional Review Board (IRB) Approval to Advance
   Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of
   Care for Non-Healing Diabetic Foot Ulcers
 * BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5
   Million
 * OUR SCIENCE
 * PRODUCTS
 * RESOURCES
 * ABOUT US
 * CONTACT US
 * FAQS
 * CAREERS
 * TERMS AND CONDITIONS
 * PRIVACY POLICY
 * SHIPPING POLICY
 * REFUND POLICY
 * COOKIE POLICY
 * I Accept

Open Accessibility Panel